Eric Joseph of JP Morgan, Maintained "Akero Therapeutics, Inc." (AKRO) at Buy with Increased Target from $49 to $62 on, Sep 5th, 2023.
Eric has made no other calls on AKRO in the last 4 months.
There are 4 other peers that have a rating on AKRO. Out of the 4 peers that are also analyzing AKRO, 0 agree with Eric's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Eric
- Eliana Merle of "UBS" Initiated at Strong Buy and Held Target at $83 on, Monday, August 28th, 2023
- Michael Ulz of "Morgan Stanley" Maintained at Buy with Increased Target to $70 on, Monday, June 12th, 2023
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $64 on, Wednesday, June 7th, 2023
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, May 17th, 2023
